Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 2;11:620907. doi: 10.3389/fonc.2021.620907

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Yin, Yang, Zhu, Xian, Han, Huang, Peng, Zhang and Zhao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The role of heat shock protein 90 (Hsp90) in multi-drug resistance (MDR) of ovarian cancer. (A) Western blotting for Hsp90 expression in A2780, A2780/Taxol, and A2780/CDDP cells. GAPDH was used as the internal control. (B) Western blotting to show relative quantitation of Hsp90 expression normalized to GAPDH using Image J analysis. (C) The sensitivity of paclitaxel in A2780 and A2780/Taxol cells transfected with/without shNC or shHsp90, was assessed using MTT assays. (D) The IC50 of paclitaxel in A2780 and A2780/Taxol cells transfected with/without shNC or shHsp90. (E,F) Respective western blots and relative quantitation of Hsp90 in A2780 and A2780/Taxol cells transfected with/without shNC or shHsp90. (G,H) Respective sensitivity and IC50 of cisplatin in A2780 and A2780/CDDP cells transfected with/without shNC or shHsp90. (I,J) Respective western blots and relative quantitation of Hsp90 in A2780 and A2780/CDDP cells transfected with/without shNC or shHsp90. (K,L) Respective sensitivity and IC50 of paclitaxel in A2780 and A2780/Taxol cells treated with DMSO or BIIB021. (M,N) Respective sensitivity and IC50 of cisplatin in A2780 and A2780/CDDP cells treated with DMSO or BIIB021. (O,P) Respective sensitivity and IC50 of cisplatin in A2780 and A2780/Taxol cells transfected with/without shNC or shHsp90. (Q,R) Respective sensitivity and IC50 of paclitaxel in A2780 and A2780/CDDP cells transfected with/without shNC or shHsp90. (S,T) Respective sensitivity and IC50 of cisplatin in A2780 and A2780/Taxol cells treated with DMSO or BIIB021. (U,V) Respective sensitivity and IC50 of paclitaxel in A2780 and A2780/CDDP cells treated with DMSO or BIIB021. The results of western blotting were analyzed using Image J. The IC50 was calculated from the survival curves generated using the Bliss method (mean ± SD of 3 independent experiments). *P < 0.05.